A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA

Recruiting now · Phase 1

Conditions studied: Multiple System Atrophy (MSA), Parkinson's Disease (PD)

In brief

The non-randomized, open-label phase I study aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and pharmacokinetics of SST001 in healthy volunteers, patients with MSA and patients with PD.

Key facts

Study ID

NCT07604116

Run by

Synusight Biotech (Shanghai) Co., Ltd.

People needed

30

Starts

2026-06-15

Expected to finish

2027-02-01

Last updated by the study team

2026-06-30

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Sign the informed consent form approved by IEC.
• Male or female participants aged ≥40 years old.
• Adequate organ functions.
• Proper contraception methods.
• Willingness to follow the study procedures.
• Additional inclusion criteria for healthy volunteers: Good health status; no history of motor disorders or cognitive disorders.
• Additional inclusion criteria for MSA: Diagnosed with clinically established or clinically probable MSA according to the MDS MSA criteria (2022). If previously treated, the treatment regimen for MSA must have been stable for at least 4 weeks with no planned adjustments in the near term.
• Additional inclusion criteria for PD: Diagnosed with clinically established or clinically probable PD according to the MDS PD criteria (2015). If previously treated, the treatment regimen for PD must have been stable for at least 4 weeks with no planned adjustments in the near term.

You may not qualify if…

• Being pregnant or lactating.
• History of other severe neurological disorders.
• History of serious or uncontrolled medical condition.
• Active HBV/HCV/HIV infection, etc.
• History of abuse of drugs or alcohol within 1 year.
• Allergy to the study drug.
• Intolerance to PET/CT or MRI (e.g. claustrophobia).
• Any interventional clinical studies within 30 days.
• Radiation exposure dose exceeding 50 mSv/year.
• Prior therapy targeting α-Syn.
• Other ineligible conditions for this study.

Where it is running

• Affiliated Hospital of Jiangnan University — Wuxi, Jiangsu, China (enrolling)
• Huashan Hospital, Fudan University — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.